NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW)

CUSIP: N62509117

Q3 2024 13F Holders as of 30 Sep 2024

Share change
+34,544
SEC-reported price per share
$7.00
Indexed holders
11
Value change
+$241,907
Number of buys
2
Number of sells
2

Security key

N62509117

Report period

Q3 2024

Indexed institutions

11

Top holders

10

Ownership snapshot

Top reported holders of NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Frazier Life Sciences Man...
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
0/15
Latest evidence
30 Jun 2024
13F Highest disclosed value: $239,242,479 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Frazier Life Sciences Management, L.P. has the largest disclosed position value at $239.24M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Frazier Life Sciences Management, L.P.'s linked filing trail.
Disclosed position value Top 5
Frazier Life Sciences Management,... $239.24M
FCPM III SERVICES B.V. $227.28M
Bain Capital Life Sciences Invest... $202.08M
RA CAPITAL MANAGEMENT, L.P. $157.82M
VIKING GLOBAL INVESTORS LP $154.15M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Frazier Life Sciences Management, L.P.
13F
Company
13F
—
mixed-class rows
$239,242,479
12,727,276 shares
mixed-class rows
— 30 Jun 2024
FCPM III SERVICES B.V.
13F
Company
13F
—
denominator unverified
$227,282,366
11,831,461 shares
— 30 Jun 2024
Bain Capital Life Sciences Investors, LLC
13F
Company
13F
—
mixed-class rows
$202,075,869
10,573,913 shares
mixed-class rows
— 30 Jun 2024
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
—
mixed-class rows
$157,816,104
8,397,333 shares
mixed-class rows
— 30 Jun 2024
VIKING GLOBAL INVESTORS LP
13F
Company
13F
—
denominator unverified
$154,151,894
8,024,565 shares
— 30 Jun 2024
Medicxi Ventures Management (Jersey) Ltd
13F
Company
13F
—
denominator unverified
$55,124,344
2,869,565 shares
— 30 Jun 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
11
Shares
1,331,215
Indexed holders
11
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q3 2024 vs Q2 2024 Across Filers

Q2 2024 indexed holders
10
Q3 2024 indexed holders
11
Indexed holder difference
1
Investor Q2 2024 Shares Q3 2024 Shares Share Diff Share Chg % Q2 2024 value Q3 2024 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .